FDA Approval of Recorlev: Xeris Biopharma Holdings Inc. (XERS) Bullish After Hours
Gule Rukhsar
December 31, 2021
Xeris Biopharma Holdings Inc. (XERS) became bullish on the news of its Recorlev® receiving FDA approval for Cushing’s syndrome patients. Consequently, the stock was trading